At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
BioWorld1d
Vertex wins FDA nod for Journavx, new mechanism for acute pain
An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...
verywellhealth1d
New FDA-Approved Painkiller Is a Safer Alternative to Opioids
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Scientific American1d
What Is Journavx, the New Opioid-Free Painkiller from Vertex?
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Palm Beach Daily News1d
FDA approves new pain medicine as opioid alternative. What to know about Journavx
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
FDA approved the first new kind of pain medication in 27 years. Here’s how it works
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
US open: Stocks jump on the back of slightly better-than-expected data
Wall Street was moving higher still shortly after the open, on the back of slightly better-than-expected readings for US ...
What's Happening With VRTX Stock?
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Investor's Business Daily on MSN1d
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
Antibiotic Collaboration and Licensing Deals Trends and Analysis Report 2024: Access 133 Agreements Signed by the World's Leading Biopharma Companies
The "Antibiotic Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Antibiotic Collaboration and Licensing Deals provides a comprehensive ...